Suchergebnisse
Octopus Titan VCT
WKN: A0NBX3 / Name: Octopus Titan VCT / Aktie / Investment Banking & Finanzdienstleistungen / Micro Cap /
Vinacapital Vietnam Opp.
WKN: A1428J / Symbol: VCVOF / Name: Vina Cap Vietnam / Aktie / Investmentfonds / Small Cap /
Visteon Corporation
WKN: A1C6VY / Symbol: VC / Name: Visteon / Aktie / Fahrzeuge & Fahrzeugteile / Small Cap /
Victory Capital Holdings Inc
WKN: A2JDX0 / Symbol: VCTR / Name: Victory Capital Holdings / Aktie / Investment Banking & Finanzdienstleistungen / Small Cap /
Should You Invest in the Vanguard Consumer Discretionary Index Fund ETF Shares (VCR)?
If you're interested in broad exposure to the Consumer Discretionary - Broad segment of the equity market, look no further than the Vanguard Consumer Discretionary Index Fund ETF Shares (VCR), a
Is Vanguard Consumer Staples Index Admiral (VCSAX) a Strong Mutual Fund Pick Right Now?
Looking for a Large Cap Blend fund? You may want to consider Vanguard Consumer Staples Index Admiral (VCSAX) as a possible option. The fund does not have a Zacks Mutual Fund Rank, though we have
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Veracyte (VCYT). Shares have added about 18.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading
Brickell Biotech Inc.
WKN: A3DMHL / Symbol: BBI / Name: Brickell Biotech / Aktie / Micro Cap /
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
Veracyte VCYT is well poised to grow in the upcoming quarters owing to its ongoing sales momentum of Afirma and Decipher Prostate tests. Meanwhile, operational headwinds from macroeconomic pressures




